Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 07/28/25
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 07/24/25
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 EarningsZacks Investment Research • 07/23/25
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/21/25
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025Business Wire • 07/14/25
3 Stocks With Upgraded Broker Ratings to Consider for Solid ReturnsZacks Investment Research • 06/27/25
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?Zacks Investment Research • 06/24/25
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2Zacks Investment Research • 06/24/25
Exelixis Surges On Positive Results For Next-Gen Colon Cancer DrugInvestors Business Daily • 06/23/25
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal CancerBusiness Wire • 06/22/25
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 06/20/25